TGFB1 and benign prostatic hyperplasia: Fluoroquinazoline derivative kzl054 inhibits the progression of BPH by targeting β-tubulin to reduce TGF-β1 secretion in WPMY-1 cells and inhibits EMT in BPH-1 cells.